Company news

Quanterix Corporation news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Quanterix Highlights Compelling Benefits of Akoya Biosciences Acquisition

March 3, 2025

Quanterix Releases Preliminary Financial Results for the Third Quarter of 2024

November 11, 2024

Quanterix Welcomes Ivana Magovčević-Liebisch, Ph.D., J.D. to Board of Directors

October 1, 2024

Quanterix Announces Commercialization of p-Tau 217 Test Kit

September 29, 2024

Quanterix Releases Financial Results for the Second Quarter of 2024

August 7, 2024

Quanterix To Report Second Quarter 2024 Financial Results

July 30, 2024

Quanterix Presents Data Demonstrating Successful Multi-Marker Approach for Alzheimer’s Disease Detection that is More Effective than Standalone Plasma p-Tau 217

July 28, 2024

Quanterix Releases Financial Results for the First Quarter of 2024

May 6, 2024

Quanterix To Report First Quarter 2024 Financial Results

April 28, 2024

Quanterix Granted Breakthrough Device Designation from U.S. FDA for Blood-Based p-Tau 217 Test for Alzheimer’s Disease

March 3, 2024

Quanterix Releases Operating Results for Fourth Quarter and Full Year 2023

February 28, 2024

Quanterix Reschedules Q4 and Full Year 2023 Earnings Conference Call; Reaffirms 2023 Guidance

February 25, 2024

Quanterix Announces First Collaborations with Five Health Networks to Aid the Diagnosis and Clinical Management of Individuals with Alzheimer’s Disease

February 25, 2024

Quanterix Releases Operating Results for Third Quarter 202

November 5, 2023

Quanterix Launches High Accuracy p-Tau 217 Blood Biomarker Test to Aid Physician Diagnosis of Alzheimer’s Disease

October 23, 2023

Quanterix Announces New Agreement to Advance Blood Based Alzheimer's Disease Detection

October 22, 2023

William P. Donnelly Appointed to Quanterix’s Board of Directors

August 20, 2023

Quanterix Appoints Vandana Sriram as Chief Financial Officer

August 8, 2023

Quanterix Releases Operating Results for Second Quarter 2023

August 6, 2023

Quanterix to Report Second Quarter 2023 Financial Results on August 8, 2023

July 19, 2023

Quanterix Launches LucentAD Biomarker Blood Test to Aid Physician Diagnosis of Alzheimer’s Disease in Patients

July 5, 2023

Quanterix Releases Operating Results for First Quarter 2023

May 8, 2023

Quanterix Releases Operating Results for Fourth Quarter and Full Year 2022; Aligned with Expectations

March 5, 2023

Quanterix Expands Laboratory Developed Test Menu with Launch of Neurofilament Light Chain Test

January 8, 2023

Quanterix Announces Appointment of Brian Blaser to Board of Directors

January 8, 2023

Quanterix Corporation Releases Operating Results for Third Quarter 2022

November 7, 2022

Quanterix Corporation Releases Operating Results for Second Quarter 2022, Announces Business Re-Alignment Plan and Revises 2022 Guidance

August 7, 2022

Quanterix Announces the Resignation of Kevin Hrusovsky as Executive Chairman of Board of Directors

August 7, 2022

Quanterix Launches First pTau-181 Plasma Laboratory Developed Test for Clinical Diagnostic and Research Applications in the U.S.

July 26, 2022

Quanterix Announces Appointment of Karen A. Flynn to Board of Directors

June 5, 2022

Quanterix Corporation Releases Operating Results for First Quarter 2022

May 9, 2022

Quanterix Corporation to Release First Quarter 2022 Financial Results on May 10, 2022

May 2, 2022

Quanterix Granted Breakthrough Device Designation from U.S. FDA for NfL Test for Multiple Sclerosis

April 21, 2022

Quanterix’ Simoa® Technology Powers Large, International Comprehensive Reference Range Study Utilizing Serum Neurofilament Light (sNfL) to Assess Disease Activity in Multiple Sclerosis (MS) Patients

April 3, 2022

Quanterix Corporation Releases Operating Results for Fourth Quarter and Full Year 2021

February 28, 2022

Quanterix Announces New Agreements with Lilly to Advance Alzheimer’s Disease Diagnosis and Treatment

February 28, 2022

Quanterix Announces Executive Leadership Succession Plan

February 28, 2022

Quanterix Provides Operational and Preliminary Financial Highlights

January 12, 2022

Quanterix Corporation Releases Operating Results for Third Quarter of 2021

November 3, 2021

Quanterix Corporation to Release Third Quarter 2021 Financial Results on Nov. 4, 2021

October 27, 2021

Quanterix Granted Breakthrough Device Designation from U.S. FDA for Blood-Based pTau-181 Assay for Alzheimer’s Disease

October 10, 2021

Quanterix Receives Label Expansion on Emergency Use Authorization for COVID Antigen Test

September 12, 2021

Quanterix Corporation Releases Operating Results for Second Quarter of 2021

August 4, 2021

Quanterix Appoints Michael Doyle as Chief Financial Officer

June 27, 2021

Quanterix Appoints Masoud Toloue as President of Quanterix and Diagnostics

May 10, 2021

Quanterix Corporation Releases Operating Results for First Quarter 2021

May 4, 2021

Quanterix Appoints Laurie Olson to Board of Directors

April 27, 2021

Quanterix Announces Appointment of Interim Chief Financial Officer

April 20, 2021

Quanterix Corporation Releases Operating Results for Fourth Quarter and Full Year 2020

March 1, 2021

Quanterix Corporation to Release Fourth Quarter and Full Year 2020 Financial Results on March 2, 2021

February 22, 2021

← Newer news releases · Older news releases →

Calls

The 5 newest of 21 calls. Every call is listed under its year.

Decks

The 5 newest of 41 decks. Every deck is listed under its year.